Yes, there are many things that come together to make human beings special, but if we are being honest, nothing does the job quite like our tendency to grow on a consistent basis. This tendency, in particular, has already allowed us to hit upon some significant milestones along the way, with one of them being a famous idea called technology. The reason why technology appears as such a popular concept is surely centred upon its unprecedented skill-set. Nevertheless, it is also, at the same time, inspired by how those skills were executed in the real-world setting, as that’s really what pushed the creation to achieve a spectrum-wide presence. Now, when you are working alongside an expansive setup of this sort, you naturally go on to manufacture several beneficiaries in the process. A representation of the same is evident in the way it all went down around our healthcare sector. In fact, technology’s linkup with healthcare couldn’t have come at a better time, considering how badly sector was struggling against its own outdated structure. Interestingly enough, though, even after giving the sphere a whole new life, the medtech concept will continue to scale up the picture under one capacity or the other. One recent development seems to reinforce this very pattern big time.
Viome Life Sciences, a biotech based in Bellevue, Washington, has officially launched CancerDetect, which is a diagnostic test for oral and throat cancer. Costing around $399, the device in question uses mRNA technology, along with an AI-powered platform, to make all the given calculations. If an individual wishes to take a test through CancerDetect, they must start by heading to Viome’s website. There, they’ll be asked to fill out a questionnaire that is designed to glean information about the consumer’s age, health habits, whether they smoke or not, and various other factors. These answers are then sent to PWNHealth, a New York-based healthcare provider that is on the list of Viome’s partners. PWNHealth meticulously reviews every answer before defining your eligibility. In case you are deemed eligible, a test is shipped to your address. Once the test has been received, the next stop calls for the consumer to provide a saliva sample right after they wake up in the morning. The consumer’s job is done as soon as they take the sample and send it back to Viome’s lab, where the company tests it using meta transcriptomics, which identifies RNA and is able to detect cancer as early as Stage 1. Lastly, a follow-up procedure is put-together in accordance with the person’s results.
“As an industry leader on a mission to identify and address the roots of chronic disease, we have been working for years to bring to market clinically-backed diagnostics solutions for cancer detection and other life-threatening and debilitating diseases. With the launch of CancerDetect™ for Oral and Throat Cancer, we have achieved this goal and plan to follow this in rapid succession with detection tools for additional life-threatening chronic diseases and cancers,” said said Naveen Jain, Founder and CEO of Viome Life Sciences.
CancerDetect has already proven itself in the laboratory environment, and the results obtained from a clinical study prove that big time. Talk about the results, they showed how the device had 95% specificity, meaning there are few false-positives, and 90% sensitivity, meaning there are few false negatives.
